Clinical Trials Browser

Phase 1 × Diabetes Mellitus, Insulin-Dependent, 12 × 90 days × Clear all

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT06564623 2026-05-08

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Phase 1 Recruiting

25 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

NCT05142189 2026-04-14

LuCa-MERIT-1

Phase 1 Recruiting

320 enrolled

EndocrineThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

NCT07476326 2026-04-03

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

Phase 1 Not yet recruiting

120 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms

NCT03293784 2026-03-30

TICIMEL

Phase 1 Completed

33 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

Clinical Trials

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

LuCa-MERIT-1

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

TICIMEL